Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

NCT ID: NCT04487236

Last Updated: 2025-08-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-15
• Study Completion Date: 2025-04-16

Brief Summary

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.

The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

Detailed Description

Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.

Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. In phase 1b, patients with HER2-positive advanced breast cancer (including those with brain metastases) will be enrolled to receive multiple doses of ZN-A-1041 in combination with Capecitabine and Trastuzumab.

In phase 1c patients with HER2-positive breast cancer with brain metastases were planned to be enrolled to receive ZN-A-1041 in combination with Capecitabine and Trastuzumab The dose levels will be determined based on the recommended doses obtained from the Phase 1b study, and the possible changes in the dosage form and the food effect study, which will be decided by the sponsor and the investigator after discussion.

Each phase of the study includes a screening period, a treatment period and a follow-up period. During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination with Capecitabine and Trastuzumab in the subjects will be collected and analyzed, thereby providing RP2D for the subsequent clinical trials.

Conditions

Advanced Solid Tumors; HER2-positive Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ZN-A-1041 50mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 50mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 100mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 100mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 200mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 200mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 400mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 400mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 600mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 600mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 800mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 800mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 1000mg

Phase 1a:

Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle

Group Type: EXPERIMENTAL

ZN-A-1041 1000mg BID

Intervention Type: DRUG

Orally 21days for one cycle

ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

Phase 1b:

ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.

Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.

Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.

If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

Group Type: EXPERIMENTAL

ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle

Phase 1b:

ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.

Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.

Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.

If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

Group Type: EXPERIMENTAL

ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle

Phase 1b:

If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

Group Type: EXPERIMENTAL

ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041+Capecitabine+Trastuzumab

Phase 1c:

The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion

Group Type: EXPERIMENTAL

ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose

Interventions

ZN-A-1041 50mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 100mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 200mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 400mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 600mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 800mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 1000mg BID

Orally 21days for one cycle

Intervention Type: DRUG

ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

Intervention Type: DRUG

ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose

Intervention Type: DRUG

Other Intervention Names

ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules; ZN-A-1041 Enteric Capsules

Eligibility Criteria

Inclusion Criteria

11. ECOG performance status of 0 to 1 2. HER2-positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).

3. Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer.

i. For patients who have no brain metastases, the following criteria should be met:

1. Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies

2. Have at least one extracranial measurable lesion by RECIST v1. 1 ii. For patients with brain metastasis, the following criteria should be met:

1) Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:

1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS.

2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

iii. In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks.

4. Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases.

i. For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:

1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery

2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period

3. Have at least one measurable lesion and is suitable for accurate repeated assessable by RECIST 1.1, and the patient has an imaging-diagnosable intracranial lesion;

4. Patients should not include suspected or confirmed meningeal metastases;

5. The patient had no disease progression with previous 12 weeks' capecitabine therapy;

6. No capecitabine therapy within 6 months;

7. Patient should not previously treat with a tyrosine kinase inhibitor (TKI). Previous treatment with trastuzumab or other antibodies should be at least 3 weeks apart from the first treatment

Exclusion Criteria

1. Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration

2. There is evidence that other primary tumors are present at the same time;

3. Previous cumulative dose of doxorubicin exceeds 360mg/m2 or its equivalent dose of similar drugs;

4. CNS Exclusion - Based on screening brain MRI and clinical assessment

1. Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.)

2. Any intracranial lesion thought to require immediate local therapy

3. Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy).

4. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Suzhou Zanrong Pharma Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fei Ma, MD

Role: PRINCIPAL_INVESTIGATOR

Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

Locations

Cancer hospital Chinese academy of medical sciences

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

ZN-A-1041-101

Identifier Type: -

Identifier Source: org_study_id